Immune escape and immunotherapy of acute myeloid leukemia

Luca Vago, Ivana Gojo

Research output: Contribution to journalArticlepeer-review


In spite of the recent approval of new promising targeted therapies, the clinical outcome of patients with acute myeloid leukemia (AML) remains suboptimal, prompting the search for additional and synergistic therapeutic rationales. It is increasingly evident that the bone marrow immune environment of AML patients is profoundly altered, contributing to the severity of the disease but also providing several windows of opportunity to prompt or rewire a proficient antitumor immune surveillance. In this Review, we present current evidence on immune defects in AML, discuss the challenges with selective targeting of AML cells, and summarize the clinical results and immunologic insights from studies that are testing the latest immunotherapy approaches to specifically target AML cells (antibodies, cellular therapies) or more broadly reactivate antileukemia immunity (vaccines, checkpoint blockade). Given the complex interactions between AML cells and the many components of their environment, it is reasonable to surmise that the future of immunotherapy in AML lies in the rational combination of complementary immunotherapeutic strategies with chemotherapeutics or other oncogenic pathway inhibitors. Identifying reliable biomarkers of response to improve patient selection and avoid toxicities will be critical in this process.

Original languageEnglish
Pages (from-to)1552-1564
Number of pages13
JournalJournal of Clinical Investigation
Issue number4
Publication statusPublished - Apr 1 2020

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Immune escape and immunotherapy of acute myeloid leukemia'. Together they form a unique fingerprint.

Cite this